Alpha-1-Antitrypsin Deficiency

  • BlackRock Inc. Boosts Position in Intellia Therapeutics Inc (NASDAQ:NTLA) – Fairfield Current
    Read More
  • Kamada Ltd. (KMDA) Given Average Recommendation of “Hold” by Analysts – Fairfield Current
    Read More
  • Jan 30, 2019 finexaminer.com
    Reviewing Intrexon Corporation (XON)’s and Intellia Therapeutics Inc. (NASDAQ:NTLA)’s results – The FinExaminer
    Read More
  • Jan 30, 2019 whatsonthorold.com
    Kamada Ltd. (KMDA) Analysts See $0.15 EPS | Thorold News – Thorold News
    Read More
  • Jan 30, 2019 dminute.com
    Comparison of Stellar Biotechnologies Inc. (SBOT) and Intellia Therapeutics Inc. (NASDAQ:NTLA) – D Minute
    Read More
  • Jan 30, 2019 dminute.com
    Reviewing Arrowhead Pharmaceuticals Inc. (ARWR)’s and Cytori Therapeutics Inc. (NASDAQ:CYTX)’s results – D Minute
    Read More
  • Reviewing Adverum Biotechnologies (NASDAQ:ADVM) and China Biologic Products (CBPO) – Fairfield Current
    Read More
  • Jan 30, 2019 dminute.com
    Intercept Pharmaceuticals Inc. (ICPT) and Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) Comparing side by side – D Minute
    Read More
  • Jan 30, 2019 honestversion.com
    Alpha 1 Antitrypsin Deficiency Treatment Market share will expand till 2023 – Honest Version
    Read More

Connect. Empower. Inspire.